These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19775480)

  • 21. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
    Tsavaris N; Lazaris A; Kosmas C; Gouveris P; Kavantzas N; Kopterides P; Papathomas T; Agrogiannis G; Zorzos H; Kyriakou V; Patsouris E
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):391-8. PubMed ID: 19083133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Sulzyc-Bielicka V; Bielicki D; Binczak-Kuleta A; Kaczmarczyk M; Pioch W; Machoy-Mokrzynska A; Ciechanowicz A; Gołębiewska M; Drozdzik M
    Genet Test Mol Biomarkers; 2013 Nov; 17(11):799-806. PubMed ID: 23968134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
    Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
    Thomaidis T; Maderer A; Formentini A; Bauer S; Trautmann M; Schwarz M; Neumann W; Kittner JM; Schad A; Link KH; Rey JW; Weinmann A; Hoffman A; Galle PR; Kornmann M; Moehler M
    J Exp Clin Cancer Res; 2014 Oct; 33(1):83. PubMed ID: 25272957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
    Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.
    Jensen SA; Vainer B; Sørensen JB
    Int J Cancer; 2007 Feb; 120(3):694-701. PubMed ID: 17096352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
    Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
    Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer.
    Sugiyama Y; Kato T; Nakazato H; Ito K; Mizuno I; Kanemitsu T; Matsumoto K; Yamaguchi A; Nakai K; Inada K; Tatematsu M
    Anticancer Drugs; 2002 Oct; 13(9):931-8. PubMed ID: 12394256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
    Ikeguchi M; Arai Y; Maeta Y; Ashida K; Katano K; Wakatsuki T
    Surg Today; 2011 Sep; 41(9):1196-9. PubMed ID: 21874414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
    Horisberger K; Erben P; Muessle B; Woernle C; Stroebel P; Kaehler G; Wenz F; Hochhaus A; Post S; Willeke F; Hofheinz RD;
    Anticancer Drugs; 2009 Jul; 20(6):519-24. PubMed ID: 19436196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
    Paolicchi E; Vivaldi C; De Gregorio V; Crea F; Fornaro L; Masi G; Loupakis F; Graziano F; Ronzoni M; Ricci V; Falcone A; Danesi R
    Oncology; 2016; 91(5):283-288. PubMed ID: 27577551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
    Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
    Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
    Bendardaf R; Lamlum H; Elzagheid A; Ristamäki R; Pyrhönen S
    Oncol Rep; 2005 Sep; 14(3):657-62. PubMed ID: 16077970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.
    Santini D; Vincenzi B; Perrone G; Rabitti C; Borzomati D; Caricato M; La Cesa A; Grilli C; Verzì A; Coppola R; Tonini G
    Oncology; 2004; 67(2):135-42. PubMed ID: 15539918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer.
    Karlberg M; Ohrling K; Edler D; Hallström M; Ullén H; Ragnhammar P
    Anticancer Res; 2010 Feb; 30(2):645-51. PubMed ID: 20332484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.
    Popat S; Chen Z; Zhao D; Pan H; Hearle N; Chandler I; Shao Y; Aherne W; Houlston R
    Ann Oncol; 2006 Dec; 17(12):1810-7. PubMed ID: 16971666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
    Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Domagala W
    Cell Oncol (Dordr); 2014 Feb; 37(1):17-28. PubMed ID: 24277474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.